Analysis of the proteomic profiles in serum of mice treated with RadioDefender, a novel radiation medical countermeasure
Abstract
Exposure to high doses of ionizing radiation arising from nuclear attacks or radiological emergencies can result in the development of acute radiation syndrome (ARS). Current treatments for ARS are limited to radiomitigators that help restore immune cell and platelet production along with bone marrow function. However, there are no radioprotectors available for use as a prophylaxis for military and first responders, although many are under investigation. RadioDefender is a candidate radioprotective agent derived from amifostine, a limited-use drug with radioprotective properties. Previous investigations in pre-treated human hematopoietic stem cells exposed to γ-radiation and mouse survival studies have shown that this candidate drug improves cell viability, supporting its potential for further development as a radioprotector. In this study, mice were treated with a single dose of either RadioDefender (250, 500, 600, or 700 mg/kg) or vehicle 24 hours prior to 9.2 Gy total-body γ-irradiation. Blood was collected at 30 days post-irradiation, and serum was isolated for proteomic analysis. As part of a larger investigation into the safety of RadioDefender, this study was performed to assess the efficacy of selected doses in combination with radiation exposure. Serum proteomic profiles of vehicle- and RadioDefender-treated animals were compared to healthy controls as an exploratory investigation of proteomic differences among animals surviving to 30 days post-irradiation. At 30 days post-irradiation, minimal differences in serum proteomic abundance were observed between any of the groups, suggesting that both irradiation- and drug-induced changes may have subsided by this time point.
Related
- Plasma proteomic profiles associated with low-dose computed tomography findings and incident lung cancer: a prospective pilot study
- Brain-Derived pTau217 and Plasma Proteomic Profiles Across Cognitive and Dementia Groups in Congolese Older Adults
- Radiation-Associated Lung Adenosquamous Carcinoma Diagnosed by Robotic-Assisted Bronchoscopy With Cone-Beam CT Guidance and Treated With Robotic Superior Segmentectomy: A Case Report
- Radiation-Induced Xerostomia in Patients With Head and Neck Cancer Treated With Comprehensive Salivary Gland-Sparing Helical Tomotherapy Technique Based on a Back Propagation Artificial Neural Network
- Oligoprogressive Renal Cell Carcinoma Treated with Stereotactic Body Radiation Therapy Versus Switching to a New Systemic Therapy
BibTeX
@article{carpenter2026analysis,
title = {{Analysis of the proteomic profiles in serum of mice treated with RadioDefender, a novel radiation medical countermeasure}},
author = {Alana D. Carpenter and Benjamin E. Packer and Xu Li and Jeyalakshmi Kandhavelu and Yaoxiang Li and Sarah A. Petrus and Oluseyi O. Fatanmi and Stephen Y. Wise and Jason Zhiguo Zhou and Amrita K. Cheema and Vijay K. Singh},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-77456-y},
url = {https://www.nature.com/articles/s41598-026-77456-y},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Analysis of the proteomic profiles in serum of mice treated with RadioDefender, a novel radiation medical countermeasure
AU - Alana D. Carpenter
AU - Benjamin E. Packer
AU - Xu Li
AU - Jeyalakshmi Kandhavelu
AU - Yaoxiang Li
AU - Sarah A. Petrus
AU - Oluseyi O. Fatanmi
AU - Stephen Y. Wise
AU - Jason Zhiguo Zhou
AU - Amrita K. Cheema
AU - Vijay K. Singh
PY - 2026
DA - 2026/10/28
JO - Scientific Reports
DO - 10.1038/s41598-026-77456-y
UR - https://www.nature.com/articles/s41598-026-77456-y
AB - Exposure to high doses of ionizing radiation arising from nuclear attacks or radiological emergencies can result in the development of acute radiation syndrome (ARS). Current treatments for ARS are limited to radiomitigators that help restore immune cell and platelet production along with bone marrow function. However, there are no radioprotectors available for use as a prophylaxis for military and first responders, although many are under investigation. RadioDefender is a candidate radioprotective agent derived from amifostine, a limited-use drug with radioprotective properties. Previous investigations in pre-treated human hematopoietic stem cells exposed to γ-radiation and mouse survival studies have shown that this candidate drug improves cell viability, supporting its potential for further development as a radioprotector. In this study, mice were treated with a single dose of either RadioDefender (250, 500, 600, or 700 mg/kg) or vehicle 24 hours prior to 9.2 Gy total-body γ-irradiation. Blood was collected at 30 days post-irradiation, and serum was isolated for proteomic analysis. As part of a larger investigation into the safety of RadioDefender, this study was performed to assess the efficacy of selected doses in combination with radiation exposure. Serum proteomic profiles of vehicle- and RadioDefender-treated animals were compared to healthy controls as an exploratory investigation of proteomic differences among animals surviving to 30 days post-irradiation. At 30 days post-irradiation, minimal differences in serum proteomic abundance were observed between any of the groups, suggesting that both irradiation- and drug-induced changes may have subsided by this time point.
SN - 2045-2322
ER -